Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions.
(1) Serotonin reuptake inhibitor antidepressants are not teratogenic in animals.  (2) Human data are limited, and most involve fluoxetine.  (3) No data pointing to a teratogenic effect after fluoxetine exposure during the first trimester have been reported.  (4) Self-resolving neurological signs have been observed in newborns exposed to fluoxetine at the end of pregnancy.  (5) The paucity of data requires all prescribers of antidepressants to pregnant women to report any adverse events occurring in a child or mother to a teratogenicity or pharmacovigilance centre.
D000014:Abnormalities, Drug-Induced; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects* / Q000627:therapeutic use; D016666:Fluvoxamine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy / Q000187:drug effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D020280:Sertraline / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D016666:Fluvoxamine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline